Rentschler Biopharma Unveils New Production Line in Massachusetts

Rentschler Biopharma SE announced that its new state-of-the-art production line in Milford, Massachusetts, is now fully operational. This marks the largest expansion in the company's 150-year history.

The new facility, initially called the Rentschler Biopharma Manufacturing Center, began its groundbreaking in August 2021. It has since added 22,000 square feet of cleanroom space and is equipped with four new 2,000L bioreactors.

The facility aims to double the company's global cGMP capacity, focusing on the commercial production of complex molecules. The original Milford site has also transitioned from a single-product to a multi-product facility.

CEO Benedikt von Braunmühl highlighted the importance of this milestone, emphasizing strong U.S. capabilities and partnerships in biopharmaceutical innovation. President Tom Roberts also noted the facility's critical role in expanding client support and tackling complex biopharmaceutical challenges.